1. Smelick, G.S., et al., Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development. Molecular pharmaceutics, 2013. 10(11): p. 4055-4062.
2. Wedemeyer, R.-S. and H. Blume, Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Safety, 2014. 37(4): p. 201-211.
3. Budha, N.R., et al., Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy? Clinical Pharmacology & Therapeutics, 2012. 92(2): p. 203-213.
4. Mudie, D.M., et al., Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State. Molecular Pharmaceutics, 2014. 11(9): p. 3039-3047.
5. Riechelmann, R.P. and M.K. Krzyzanowska, Drug interactions and oncological outcomes: a hidden adversary. ecancermedicalscience, 2019. 13.
6. Hilton, J.F., et al., An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer, 2013. 82(1): p. 136-142.
7. Kumarakulasinghe, N.B., et al., EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget, 2016. 7(51).
8. Vishwanathan, K., et al., The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. The Journal of Clinical Pharmacology, 2018. 58(4): p. 474-484.
9. Spring, L.M., et al., Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet, 2020. 395(10226): p. 817-827.
10. Finn, R.S., et al., Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2016. 375(20): p. 1925-1936.
11. Hortobagyi, G.N., et al., Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016. 375(18): p. 1738-1748.
12. Slamon, D.J., et al., Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol, 2018. 36(24): p. 2465-2472.
13. Turner, N.C., et al., Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018. 379(20): p. 1926-1936.
14. Samant, T.S., et al., Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations. Clinical Pharmacology & Therapeutics, 2018. 104(2): p. 374-383.
15. Sun, W., et al., Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions. Clinical Pharmacology in Drug Development, 2017. 6(6): p. 614-626.
16. Lu, Y., et al., Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients. The Journal of Clinical Pharmacology, 2021. 61(8): p. 1054-1068.
17. Cardoso, F., et al., 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)††These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO). Annals of Oncology, 2018. 29(8): p. 1634-1657.
18. Willemsen, A.E.C.A.B., et al., Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discovery Today, 2016. 21(6): p. 962-976.
19. van Leeuwen, R.W.F., et al., Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. The Lancet Oncology, 2014. 15(8): p. e315-e326.
20. IBRANCE®, Full Prescribing Information. 2016.
21. van Leeuwen, R.W.F., et al., Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clinical Pharmacokinetics, 2017. 56(7): p. 683-688.
22. Del Re, M., et al., Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO open, 2021. 6(5): p. 100231.
23. Goldstein, M.J., et al., Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies. Clinical and Translational Science, 2021. 14(2): p. 536-543.
24. Braal, C.L., et al., Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 2021. 81(3): p. 317-331.
25. de Gooijer, M.C., et al., P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Investigational New Drugs, 2015. 33(5): p. 1012-1019.
26. Martínez-Chávez, A., et al., P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Molecular pharmaceutics, 2019. 16(9): p. 3842-3852.
27. Ollier, E., et al., In vitro and in vivo evaluation of drug–drug interaction between dabigatran and proton pump inhibitors. Fundamental & Clinical Pharmacology, 2015. 29(6): p. 604-614.
28. Fang, Y.-H., et al., Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study. Cancer management and research, 2019. 11: p. 8539.
29. Ha, V.H., et al., Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? Journal of Oncology Pharmacy Practice, 2014. 21(3): p. 194-200.
30. Lalani, A.-K.A., et al., Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017. 15(6): p. 724-732.
31. McAlister, R.K., et al., Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma. The Oncologist, 2018. 23(6): p. 686-692.
32. Veerman, G.D.M., et al., Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. Clinical Pharmacokinetics, 2021. 60(1): p. 69-77.
33. Zenke, Y., et al., Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations. Clinical Lung Cancer, 2016. 17(5): p. 412-418.
34. Indini, A., et al., Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers, 2020. 12(4).
35. Sharma, M., et al., The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer, 2019. 125(7): p. 1155-1162.